Study of Radiolabeled Revumenib in Adults With Acute Leukemia
This is an open-label study to evaluate the absorption, metabolism, and excretion (AME) of carbon-14 (\[14C\])-revumenib in participants with acute leukemia.
Acute Leukemia
DRUG: Revumenib
Percentage of Dose Excreted in Urine (feu), Up to Day 11|Percentage of Dose Excreted in Feces (fef), Up to Day 11|Amount Excreted in Urine (Aeu), Up to Day 11|Amount Excreted in Feces (Aef), Up to Day 11|Area Under The Concentration Time Curve from Time 0 to The Last Measurable Concentration (AUC0-t), Up to Day 21|Maximum Observed Concentration (Cmax), Up to Day 21
Number of Participants with Treatment-emergent Adverse Events (TEAEs), up to approximately 1 year
Participants will be enrolled in this study primarily to complete the 11-day AME portion of the study; participants who are receiving benefit from revumenib may remain on study until progressive disease (PD) or unacceptable toxicity.